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Cardiovascular, Pulmonary and Renal Pathology
Protection against Experimental Autoimmune
Myocarditis Is Mediated by Interleukin-10-Producing
T Cells that Are Controlled by Dendritic Cells
Ya Li,* Janet S. Heuser,* Stanley D. Kosanke,†
Mark Hemric,* and Madeleine W. Cunningham*†
From the Departments of Microbiology and Immunology * and
Pathology,† University of Oklahoma Health Sciences Center,
Oklahoma City, Oklahoma
Experimental autoimmune myocarditis (EAM) can be
induced in the Lewis rat by cardiac myosin or its
cryptic S2-16 peptide epitope (amino acids1052 to
1076). To investigate cellular mechanisms and the
role of antigen-presenting cells in regulation of myo-
carditis, we induced protection against EAM in Lewis
rats by administration of S2-16 peptide in incomplete
Freund’s adjuvant (IFA). Protection to EAM was asso-
ciated with activation of S2-16-reactive splenocytes
secreting high levels of interleukin (IL)-10 and re-
duced levels of interferon- and IL-2. Adoptive trans-
fer of S2-16:IFA-induced splenocytes producing IL-10
suppressed myocarditis induction in syngeneic recip-
ients, suggesting their regulatory cell nature. How-
ever, exposure of S2-16:IFA-induced cells to inflam-
matory cytokine IL-12 converted them to Th1
effectors that transferred EAM. Differentiated func-
tion of S2-16-reactive T cells in protected rats resulted
from increased IL-10 production by dendritic cells
(DCs). Purified DCs from S2-16:IFA-treated rats pro-
moted S2-16-reactive CD4 T cells to produce in-
creased IL-10 and reduced interferon-. In addition,
adoptive transfer of IL-10-producing DCs from S2-16:
IFA-treated rats also induced protection to EAM in
recipient rats. These studies demonstrated DCs and
key cytokines, such as IL-10 and IL-12, regulated the
fate of T cells in myocarditis development in the
Lewis rat. (Am J Pathol 2005, 167:5–15)
Myocarditis is an inflammatory heart disease that can be
initiated by infectious pathogens.1–3 Dilated cardiomyop-
athy, which may follow myocarditis and represent the
chronic stage of disease, is a major cause of heart failure
and heart transplantation.4–6 Evidence suggests that au-
toimmune responses to cardiac antigens exposed after
heart damage may play an important role in prolonged
damage of myocardium.3,7–9 Nevertheless, little progress
has been made in treating myocarditis by immunosup-
pression, because a complete understanding of key fac-
tors that regulate the pathogenic immune responses in
autoimmune myocarditis are not well established.
Experimental autoimmune myocarditis (EAM) gener-
ated in susceptible mouse and rat strains by immuniza-
tion with purified cardiac myosin or a specific pathogenic
cardiac myosin peptide in adjuvant has been used to
investigate the pathogenesis of myocarditis induced by
autoimmune mechanisms.10–20 Many studies have
shown that cardiac antigen-induced myocarditis is a T-
cell-mediated disease.18,21–24 However, the active induc-
tion of EAM relies on the use of bacterial adjuvants [com-
plete Freund’s adjuvant (CFA)] during immunization,
suggesting that activation of the innate immune system is
important in disease induction.25–27 Inflammatory cyto-
kines such as interleukin (IL)-1, tumor necrosis factor
(TNF)-, and IL-12 promote myocarditis development in
animals,28–31 whereas mice that lack TNF-Rp55 or are
deficient in IL-12 signaling were protected from EAM.32,33
In vivo inhibition of co-stimulatory molecule B7-1 and
CD40 also markedly decreased myocardial inflamma-
tion.34,35 A recent study directly demonstrated that car-
diac antigen-loaded dendritic cells (DCs) induced auto-
immune myocarditis when they were activated and
transferred.36 Taken together, these studies suggest that
EAM induction is closely associated with not only the
myocarditic epitopes of cardiac myosin and their reactive
T cells, but also with the activation of antigen-presenting
cells (APCs) such as DCs by inflammatory cytokines.
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Various strategies have been used to down-regulate
cardiac myosin-specific immune responses in EAM.37–42
Nasal administration of cardiac myosin suppressed EAM
in A/J mice, and blockade of IL-10 at the time of nasal
administration of antigen abolished the effect of nasal
tolerization.40,42 Intravenous administration of syngeneic
splenocytes coupled with cardiac myosin before myocar-
ditis induction also reduced the incidence and severity of
myocarditis. Both T- and B-cell responsiveness was af-
fected after tolerization.41 In addition, administration of a
streptococcal M protein peptide, which has similarity to
cardiac myosin and could induce myocarditis in mice,
induced partial protection against coxsackieviral myocar-
ditis.39 Immune tolerance approaches and mechanisms
have also been studied in other autoimmune disease
models such as experimental autoimmune encephalomy-
elitis and experimental autoimmune uveitis.43,44
The definition of tolerance is an antigen-specific unre-
sponsiveness.45 Classic tolerance mechanisms include
T-cell anergy and clonal deletion, but accumulating evi-
dence suggests the importance of active immune sup-
pression associated with various subtypes of regulatory T
cells.46–49 Regulatory T cells occur naturally and could
be developed de novo in central and peripheral lymphoid
organs.47,48 It has been shown that DCs or cytokines
such as IL-10 were required for induction of regulatory T
cells.50,51 Therefore, APCs not only activate antigen-spe-
cific T cells, but also suppress activated T cells by certain
direct and indirect mechanisms.
It has been widely reported that animals pretreated
with antigen in incomplete Freund’s adjuvant (IFA) were
protected from inflammatory responses induced by the
same antigen in CFA.52–57 Regulatory/suppressive cells
seem to be involved in this process, because the protec-
tion is transferable. The antigen:IFA-induced immunity is
an ideal model system to study the regulatory mecha-
nisms that control the self-reactive T cells. It has been
suggested that APCs are not effectively activated after
immunization with antigen in IFA that lacks mycobacte-
ria.58–60 However, whether or how APCs are involved in
active suppression of antigen:IFA-induced unresponsive-
ness has not been studied. The aim of this study was to
induce protection to myocarditis by cardiac myosin pep-
tide and IFA administration, and to further examine the
cellular mechanisms and the role of DCs in the regulation
of T-cell responses in a Lewis rat EAM model.
We previously identified a cryptic pathogenic peptide
sequence of cardiac myosin S2 region (S2-16, amino
acids 1052 to 1076), which induced EAM in Lewis rats by
both active immunization and passive transfer of S2-16
peptide-specific T cells.20 S2-16-induced EAM was ac-
companied by up-regulation of inflammatory cytokine ex-
pression in myocardium and production by antigen-spe-
cific T cells. In this study, the S2-16-induced EAM model
was used to investigate protection to EAM by peptide
S2-16 and IFA treatment. We found that protection in-
duced by S2-16:IFA treatment was accompanied by ex-
pansion of autoreactive T cells that had impaired inter-
feron (IFN)- production and enhanced IL-10 production.
Antigen-specific T cells from S2-16:IFA-treated rats had
both regulatory and pathogenic potential that was con-
trolled by DCs and their cytokines IL-10 and IL-12. The
study directly demonstrated that DCs played a regulatory
role in antigen and IFA-induced immune protection in
EAM. The data link protection against EAM to both innate
and adaptive immunity.
Materials and Methods
Animals and Antigens
Female Lewis rats (6 to 8 weeks old) were purchased
from Harlan-Sprague-Dawley (Indianapolis, IN) and
maintained in groups of three at the Animal Resources
Facility on the campus of the University of Oklahoma
Health Sciences Center (OUHSC). All animal studies
were approved by the OUHSC animal care and use
committee. Peptide S2-16 and S2-1 from the S2 region of
cardiac myosin was synthesized and purified as a 25-mer
by Genmed Synthesis Inc. (San Francisco, CA). The
amino acid sequence of S2-16 peptide is KRKLEG-
DLKLTQESIMDLENDKQQL, and sequence of S2-1 pep-
tide is SAEREKEMASMKEEFTRLKEALEKS.20
Induction of Active EAM and Protection
For induction of EAM by active immunization, rats were
anesthetized with 10 mg of ketamine/0.2 mg of xylazine,
and were injected in one hind footpad with 0.5 mg of
S2-16 peptide emulsified in CFA (Sigma, St. Louis, MO)
at 1:1 ratio (v/v, 0.25 ml for each rat). After immunization,
the rats were given 1  1010 heat-killed Bordetella per-
tussis (Michigan Department of Public Health, Lansing,
MI) on day 1 and day 3 intraperitoneally. Seven days after
primary immunization, the rats were boosted subcutane-
ously with 0.5 mg of antigen emulsified in IFA (Sigma) at
1:1 ratio. Control rats received phosphate-buffered saline
(PBS) plus adjuvants. Rats were sacrificed at day 21 by
cardiac puncture under anesthesia. Heart, liver, and kid-
neys were fixed in 10% buffered formalin and imbedded
in paraffin. Five-m sections were cut and stained with
hematoxylin and eosin for microscopic histological exam-
ination. Myocardium was blindly scored for the presence
of histopathological myocarditis according to the scale:
0, normal; 1, mild (5% of heart cross-section involved);
2, moderate (5 to 10% of cross-section involved); 3,
marked (10 to 25% of cross-section involved); and 4,
severe (25% of cross-section involved). Valve, liver,
and kidneys were also evaluated for cellular infiltrates.
To induce protection to EAM, rats were injected intra-
peritoneally with 1.0 mg or 1.5 mg of S2-16 peptide
emulsified in IFA at 1:1 ratio (v/v, 0.5 ml for each rat).
Control rats received S2-1:IFA or PBS:IFA by intraperito-
neal injection. After 14 days, all rats were challenged by
S2-16:CFA immunization or PBS:CFA as a control, as
described in active induction of EAM. The rats were
terminated at day 21 after challenge and evaluated for
histological myocarditis. To induce suppression of EAM
by cell transfer, rats were injected in one footpad with
S2-16:IFA followed by subcutaneous boosts with S2-16:
IFA on day 7. Control rats were injected with S2-1:IFA, or
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S2-16:CFA, or PBS:CFA. Two weeks after the first injec-
tion, splenocytes from immunized rats were isolated and
cultured with S2-16 peptide (5 g/ml) for 24 hours. In
some experiments, recombinant murine IL-12 (2 ng/ml;
Peprotech, Rocky Hill, NJ) or mouse anti-rat IL-10 mono-
clonal antibody (A5-7, 10 g/ml; Pharmingen, San Diego,
CA) were added to the cell culture. Cells were then
harvested, counted, and injected intravenously into naı¨ve
6- to 8-week-old Lewis rats (108 cells in 0.5 ml of PBS per
rat). Recipients were concomitantly challenged by active
immunization with S2-16 in CFA after transfer and were
sacrificed at day 21 after challenge for histopathological
examination. Some of the recipients were sacrificed 14
days after transfer without being challenged with
S2-16:CFA.
Proliferation and Cytokine Assay
Spleens were obtained from rats and pressed through
fine mesh screens. The single cell suspension was
washed, counted by trypan blue exclusion, and resus-
pended to 5  106/ml in culture medium, containing
RPMI 1640 (Life Technologies, Inc., Grand Island, NY)
supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT), 1% sodium pyruvate, 1% nonessential amino
acids, and antibiotics (all from Life Technologies, Inc.).
The cells were plated in 96-well tissue culture plates
(Corning Inc., Corning, NY) in 100 l of culture medium.
Splenocytes were incubated at 37°C in 5% CO2 for 5
days with antigens at various concentrations before ad-
dition of 0.5 Ci tritiated thymidine (ICN, Irvine, CA). After
18 to 24 hours, cells were harvested onto filters with a
MACH II M Harvester 96 (Wallac Inc., Gaithersburg, MD)
and the tritiated thymidine incorporation was measured in
a Betaplate liquid scintillation counter (Wallac, Turku,
Finland). Values represent the stimulation index (stimula-
tion index: mean test counts per minute/mean of medium
control counts per minute). To determine cytokine pro-
duction, splenocytes were cultured in medium in the
presence of 10 g/ml of antigens for 24 to 72 hours. In
some experiments, mouse anti-rat IL-4 monoclonal anti-
body (OX-81, 5 g/ml; PharMingen), mouse anti-rat IL-10
monoclonal antibody (A5-7, 5 g/ml; PharMingen), or
recombinant murine IL-12 (1 ng/ml, Peprotech) were
added into the culture. Supernatant was collected, and
analyzed for cytokine content by enzyme-linked immu-
nosorbent assay (ELISA), according to the manufactur-
er’s protocol (PharMingen). For in vitro stimulation assay
of CD4 T cells, splenocytes were incubated with a sat-
urating concentration of magnetic anti-rat CD4 (OX-38)
microbeads (Miltenyi Biotec, Auburn, CA) at 4°C for 20
minutes. After one wash, cells were separated magneti-
cally on MS columns in a MACS separator (Miltenyi Bio-
tec). Purified CD4 T cells were then stimulated by 10
g/ml of antigen together with various concentrations of
purified DCs. Proliferative T-cell responses were as-
sessed after 72 to 96 hours in culture medium at 37°C/5%
CO2 by measuring tritiated thymidine incorporation.
Magnetic Cell Sorting of Splenic DCs,
Stimulation of DCs for Cytokine Production, and
Adoptive Transfer of DCs
Spleens were minced and digested with 2 mg/ml of col-
lagenase D (Roche Diagnosis, Meylan, France) in RPMI
1640/1% fetal calf serum/10 mmol/L ethylenediamine tet-
raacetic acid for 45 minutes at 37°C. Digested material
was pressed through steel mesh using a plunger of a
syringe. Cell suspensions were then pipetted to disperse
cells, filtered, and washed once with PBS/0.5% bovine
serum albumin/2 mmol/L ethylenediamine tetraacetic
acid. Supernatants were removed after centrifugation,
and cell pellets were resuspended and layered on an
equal volume of 14.5% (w/v) Nycodenz (Nycomed As,
Oslo, Norway)/PBS solution and centrifuged for 13 min-
utes at 1800  g and 4°C. Low-density cells at the top of
the low-density solution were collected and washed
once. Cells were then incubated with a saturating con-
centration of magnetic anti-rat DC (OX-62) microbeads
(Miltenyi Biotec) at 4°C for 20 minutes. After one wash,
cells were separated magnetically on MS columns in a
MACS separator (Miltenyi Biotec). The purity of OX-62
DCs is greater than 90% after such positive selection as
measured by flow cytometry analysis. For cytokine mea-
surement, sorted splenic rat DCs (1.25  105 cells) were
cultured in 1 ml of culture medium in 24-well plates and
incubated for 24 hours with various stimuli including 10
g/ml of anti-CD40 monoclonal antibody (HM40-3,
PharMingen), 2 g/ml of lipopolysaccharide (LPS)
(Sigma, St. Louis, MO), or 10 g/ml of CpG oligonucleo-
tide (Qiagen, Alameda, CA). TNF-, IFN-, and IL-10
were measured by sandwich ELISA according to the
manufacturer’s protocol (PharMingen). For transfer of
DCs, OX-62 DCs were isolated from rat spleens, and
incubated with 10 g/ml of S2-16 peptide, 10 g/ml of
anti-CD40 antibody (PharMingen), and 2 g/ml of LPS
(Sigma) for 12 hours. Some groups of DCs were also
treated with 5 g/ml of mouse anti-rat IL-10 antibody
(PharMingen). Cells were then washed, and 106 DCs
were adoptively transferred into naı¨ve Lewis rats. Recip-
ients were concomitantly challenged by active immuni-
zation with S2-16 in CFA after transfer and were sacri-
ficed at day 21 after challenge for histopathological
examination.
Flow Cytometry
Isolated splenic DCs (1  106) were stained with 1 g of
antibodies against rat DC (OX62) and MHC class II-PE
(OX-6, all from PharMingen), and analyzed using a
FACScalibur (Becton Dickinson, San Jose, CA) to evalu-
ate the separation of DCs from rat spleen cells. Data were
processed with Cellquest software (Becton Dickinson).
Intracellular IL-10 production by CD4 T cells was mea-
sured by flow cytometric staining according to BD cytofix/
cytoperm kit manual (PharMingen). Anti-rat CD4-Cy-
chrome (OX-35) and anti-rat IL-10-PE (A5-4, 1 g/106
cells; all from PharMingen) were used to label the cells.
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Quantification of Gene Expression by Real-Time
Polymerase Chain Reaction (PCR)
Total RNA was extracted from 106 splenic DC samples
using RNeasy mini kit (Qiagen, Valencia, CA). Reverse
transcription was performed with aliquots of each RNA
sample, random hexamers, and Superscript reverse
transcriptase according to the protocol of the Super-
Script First-Strand Synthesis System for RT-PCR (In-
vitrogen, Carlsbad, CA). Real-time quantitative PCR
was performed using an ABI Prism 7700 sequence
detector (PE Applied Biosystems, Foster City, CA).
All primers were designed using the Primer Express
software (PE Applied Biosystems). The sequences
of primer pairs specific for rat IL-12 (p40) and gly-
ceraldehyde-3-phosphate dehydrogenases (G3PDH)
are as follows: IL-12, ATCTGAAACTCCCCATGATG-
CT and CAGAGCTCCGAGTTCATTTTCC; G3PDH, TG-
CACCACCAACTGCTTAGC and GGCATGGACTGTG-
GTCATGAG. Each reaction contained 1 l of cDNA,
0.75 l of 50 mmol/L magnesium chloride, 4 l of 5
mol/L forward and reverse primer, 2.75 l of distilled
water, and 12.5 ml SYBR Green PCR Master Mix (PE
Applied Biosystems). The total reaction volume was 25
l. The negative control reaction contained distilled
water as a template. Rat G3PDH was used as an
endogenous control to allow for relative mRNA quanti-
fication. Cytokine mRNA levels are presented as the
mean  SEM fold increase in gene expression ob-
served in triplicate wells of LPS and anti-CD40 anti-
body-treated DCs relative to untreated DCs.
Statistical Analysis
Means, SD, SEMs, and unpaired Student’s t-test or Mann-
Whitney test were used to analyze the data using Graph-
Pad Prism (GraphPad Software, San Diego, CA). Groups
were considered statistically different if P  0.05.
Results
Prevention of EAM by S2-16 Peptide and IFA
Treatment
Our previous work demonstrated that S2-16 peptide, a
cryptic myocarditic epitope found in both human and
rat cardiac myosin induced myocarditis in the Lewis
rat.20 In this study, we investigate regulation of autore-
active T cells in the S2-16-induced EAM. Administra-
tion of autoantigen in IFA is well known to effectively
induce antigen-specific unresponsiveness in animal
models.54,55 As expected, Lewis rats given 1.5 mg of
S2-16 peptide in IFA intraperitoneally 2 weeks before
active immunization with 0.5 mg of the same antigen in
CFA were protected from developing EAM (Table 1).
The disease-positive control group of rats, which re-
ceived PBS and IFA pretreatment before challenge
with S2-16 peptide in CFA, experienced mild to severe
myocarditis at the rate of 80% as expected for rats
not protected. Another group of rats pretreated with a
control peptide S2-1 and IFA also developed myocar-
ditis on challenge with S2-16 in CFA (Table 1), and
suggested that protection induced by S2-16:IFA treat-
ment was not just a adjuvant effect, but was related to
S2-16-specific lymphocytes. Pretreatment of rats with
S2-16:CFA before the challenge resulted in some pro-
tection from myocarditis, but not as well as S2-16:IFA
pretreatment. As a disease-negative control, rats pre-
treated with PBS:IFA before PBS:CFA challenge failed
to develop myocarditis (Table 1). Dose titration exper-
iments showed that 1.0 mg of S2-16 peptide adminis-
tered intraperitoneally in IFA also provided protection
from EAM (data not shown).
S2-16-Reactive T Cells Proliferated in Protected
Rats, but Produced Different Cytokines
Compared to T Cells from Myocarditic Rats
We tested the ability of T cells to recall proliferative
responses against antigen in protected and diseased
rats. Splenic lymphocytes from disease-positive con-
trol rats, which were treated with PBS:IFA before S2-
16:CFA immunization, mounted recall proliferative re-
sponses to in vitro restimulation with S2-16 peptide in a
dose-dependent pattern (Figure 1A). In comparison, a
similar strength of recall proliferation was observed in
S2-16:IFA-pretreated disease-protected rats (Figure
1A). When cytokine levels in cell culture supernatants
were examined, we found that splenocytes from pro-
tected rats produced lower levels of Th1 cytokine IFN-
and IL-2 as compared with disease-positive control
rats (Figure 1B). However, IL-10, a regulatory cytokine,
was significantly higher in protected rats than in dis-
eased rats (Figure 1B). Th2 cytokine IL-4 production
was undetectable for these groups of rats (data not
Table 1. Induction of Myocarditis or Protection by Cardiac
Myosin Peptide S2-16
Pretreat-
ment
Immuni-
zation
Positive/
total
Mean histological score
(1–4)*  SD
S2-16:IFA S2-16:CFA 0/6 0†
PBS:IFA S2-16:CFA 5/6 2.6  1.6
S2-1:IFA S2-16:CFA 2/3 2.5  2
S2-16:CFA S2-16:CFA 1/3 0.3  0.3
PBS:IFA PBS:CFA 0/3 0‡
Lewis rats were pretreated with S2-16 peptide emulsified in IFA.
Control groups of rats were pretreated with PBS or S2-1 peptide in IFA,
or S2-16 in CFA. Fourteen days later, rats were challenged by
immunization with S2-16 peptide or PBS in CFA as described in
Materials and Methods. Animals were killed 21 days after challenge.
Myocarditis was identified in fixed heart tissue sections by
histopathological examination. In vitro analysis of proliferation and
cytokine production of splenocytes are shown in Figure 1.
*Lesions were scored histologically based on the following scale: 0,
normal; 1, mild (less than 5% of cross section involved); 2, moderate (5
to 10% of cross section involved); 3, marked (10 to 25% of cross
section involved); 4, severe (greater than 25% of cross section
involved).
†P  0.005 for S2-16:IFA/S2-16:CFA-treated group versus PBS:IFA/
S2-16:CFA-treated control group (Mann-Whitney test was used for in
vivo results).
‡P  0.05 for PBS:IFA/PBS:CFA-treated group versus PBS:IFA/S2-
16:CFA-treated group.
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shown). Therefore, S2-16-reactive T cells were not de-
leted or anergized in protected rats, but they produced
low levels of Th1 cytokine IFN- and IL-2 and high
levels of regulatory cytokine IL-10.
S2-16:IFA-Induced Splenocytes Protected
Naı¨ve Rats from EAM
To further illustrate that S2-16:IFA-induced protection to
EAM is a cellular process of active immune suppression,
we performed adoptive transfer experiments. Lewis rats
were treated with S2-16:IFA, and control rats were treated
with S2-1:IFA, S2-16:CFA or PBS:CFA. Two weeks later,
splenocytes from treated rats were collected, restimu-
lated with S2-16 in vitro, and transferred intravenously into
naı¨ve syngeneic recipients. As shown in Table 2, S2-16:
IFA-induced splenocytes did not transfer myocarditis to
naı¨ve recipient rats. Furthermore, they prevented myo-
carditis induction when recipients were challenged by
active immunization with S2-16:CFA. Control peptide S2-
1:IFA-induced splenocytes did not have such protective
effects. By contrast, S2-16:CFA-induced splenocytes
were pathogenic and adoptively transferred myocarditis
into syngeneic recipients. Recipients of S2-16:CFA-
induced splenocytes developed myocarditis after chal-
lenge (Table 2). As another control, cells from PBS:CFA-
treated rats did not transfer EAM into recipients, and they
also did not protect recipients from myocarditis (Table 2).
Therefore, only S2-16:IFA-induced splenocytes played a
regulatory role in controlling myocarditis.
IL-12 Stimulation or IL-10 Blockade Reversed
Protection Induced by S2-16:IFA Splenocytes
Study of splenocytes harvested from S2-16:IFA and
S2-16:CFA-primed donor rats showed comparable
proliferative responses to S2-16 peptide restimulation
in vitro, whereas cells from control PBS:CFA-treated
rats did not respond to S2-16 in the proliferation assay
(Figure 2A). These data suggested that S2-16:IFA
priming also activated autoreactive lymphocytes.
When cytokines in the culture supernatants were mea-
sured, splenocytes from S2-16:IFA-treated donor rats
did not produce high levels of Th1 cytokine IFN- and
Figure 1. S2-16:IFA-induced protection was associated with expansion of
S2-16-reactive T cells producing low levels of IFN- and IL-2 but high levels
of IL-10. Lewis rats were administered S2-16:IFA or control PBS:IFA 14 days
before challenge by immunization with S2-16:CFA. Splenic lymphocytes
were collected 21 days after challenge. A: Proliferative responses of spleno-
cytes with different concentrations of S2-16 peptide. Proliferation was mea-
sured by 3H-thymidine incorporation. Results of proliferative assay were
expressed as stimulation index (SI) (mean test counts per minute/mean of
medium control counts per minute). B: IL-2, IL-10, and IFN- production by
splenocytes cultured with S2-16. Supernatants were collected at 24 hours for
IL-2, 48 hours for IFN-, and 72 hours for IL-10, and cytokine levels were
measured by cytokine-specific ELISA. Error bars represent SEMs, and Stu-
dent’s t-test was used to determine the significant differences between PBS:
IFA-pretreated group and S2-16:IFA-pretreated group (*P  0.05, **P 
0.005). Cytokine levels of cells cultured with medium alone were 20% of
cytokine response to S2-16, and are not shown in figure.
Table 2. Adoptive Transfer of S2-16:IFA-Induced Splenocytes Resulted in Protection or Myocarditis
Donor treatment
Number of recipients with disease
Mean histological score of
heart (0–4)In vivo In vitro S2-16 plus
S2-16:IFA — 0/6 0
S2-16:IFA — 0/6 (after challenge) 0*
S2-1:IFA — 2/3 (after challenge) 2.5  1.5
S2-16:CFA — 5/6 1.6  0.6*
S2-16:CFA — 4/6 (after challenge) 1.8  1.1
PBS:CFA — 0/6 0
PBS:CFA — 3/3 (after challenge) 2.5  1.8
S2-16:IFA IL-12 5/6 1.7  0.8*
PBS:CFA IL-12 0/6 0
S2-16:IFA Anti-IL-10 3/3 (after challenge) 3.6  0.3
Lewis rats were treated with S2-16:IFA. Control rats were treated with S2-1:IFA, S2-16:CFA, or PBS:CFA. Spleen cells were obtained from each
group of animals 2 weeks after treatment, and were cultured in vitro with peptide S2-16, or S2-16 plus recombinant murine IL-12, or S2-16 plus anti-rat
IL-10 monoclonal antibody for 24 hours. Cell aliquot 108 was injected into each naı¨ve Lewis rat intravenously. The recipients were sacrificed 2 weeks
after adoptive transfer, and myocarditis was identified in the fixed heart sections by histopathological examination. Some recipients were concomitantly
challenged by active immunization with S2-16:CFA after transfer.
*P  0.05 for S2-16:IFA cell recipients versus PBS:CFA cell recipients that were challenged by S2-16:CFA immunization. P  0.05 for S2-16:CFA
cell recipients versus PBS:CFA cell recipients, and for S2-16:IFA cell (IL-12 stimulated) recipients versus PBS:CFA cell (IL-12 stimulated) recipients
(Mann-Whitney test).
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IL-2 as S2-16:CFA-induced cells did, but they pro-
duced an increased level of IL-10 regulatory cytokine
(Figure 2B). Th2 cytokine IL-4 secretion for these
groups of rats was still undetectable (data not shown).
The low level of IFN- and IL-2 production in S2-16:IFA
immunized rats was not reversed by adding anti-IL-10
antibody into the cell cultures, although IL-10 produc-
tion was inhibited in this case (Figure 2B). In contrast,
addition of IL-12, a key proinflammatory cytokine, sig-
nificantly increased IFN- and IL-2 secretion of S2-16:
IFA splenocytes (Figure 2B), which suggested that
S2-16:IFA-primed lymphocytes still have the potential
to polarize to Th1 effectors during an inflammatory
stimulation.
Consistent with in vitro results, IL-12 stimulation con-
verted the S2-16:IFA-induced splenocytes into patho-
genic effectors that transferred EAM in five of six naı¨ve
syngeneic recipients (Table 2). In contrast, spleno-
cytes from PBS:CFA-injected rats failed to transfer
EAM into recipients even after culture with S2-16 in the
presence of IL-12 (Table 2). More significantly, the
protective effect of S2-16:IFA-induced splenocytes
could be eliminated if IL-10 production from S2-16-
reactive cells was blocked by an anti-rat IL-10 antibody
before the transfer. Rats receiving anti-IL-10 antibody-
treated S2-16:IFA splenocytes regained sensitivity to
myocarditis induction (Table 2). Taken together, these
data suggest in S2-16:IFA-treated donor rats, S2-16-
reactive T cells were nonpathogenic due to reduced
inflammatory cytokines IFN- and IL-2, and became
protective by production of regulatory cytokine IL-10.
S2-16:IFA-induced lymphocytes have both pathogenic
and protective potential that depends on the cytokine
production from S2-16-specific T cells.
Effect of S2-16:IFA Treatment on Cytokine
Production of DCs
Because both cytokines IL-12 and IL-10 can be pro-
duced by APCs, especially DCs, we next tested whether
the polarization of S2-16:IFA-induced lymphocytes is
secondary to an alteration of DC function. When we mea-
sured the cytokine secretion of DCs, we found the pro-
duction of proinflammatory cytokine TNF- from DCs of
S2-16:CFA-primed rats was much higher than S2-16:IFA-
primed and untreated naive rats after LPS plus anti-CD40
antibody or CpG-containing oligonucleotide plus anti-
CD40 antibody stimulation (Figure 3). The expression of
inflammatory cytokine IL-12p40 mRNA was also up-
regulated more than twofold in S2-16:CFA DCs after
exposure to LPS and anti-CD40 antibody (Figure 3). In
contrast, IL-10 production was highly induced for S2-16:
IFA-induced DCs but not S2-16:CFA-induced DCs or
naı¨ve DCs after toll-like receptor (LPS or CpG) and CD40
stimulation (Figure 3). Therefore, these results show that
S2-16:IFA-induced DCs produced less proinflammatory
Figure 2. S2-16:IFA-primed splenocytes proliferated to S2-16 and pro-
duced low levels of IFN- and IL-2 but high levels of IL-10. Lewis rats
were treated with S2-16:IFA, and S2-16:CFA or PBS:CFA as controls.
Fourteen days later, splenic lymphocytes were collected and cultured
with S2-16 peptide to determine their in vitro recall response. A: Prolif-
erative response of splenocytes after culture with different concentrations
of S2-16. Proliferation was measured by 3H-thymidine incorporation. B:
Cytokine production of splenocytes immunized in vivo and treated in
vitro as indicated in figure and in legend above. Cell culture supernatants
were collected for measurement of IFN-, IL-2, and IL-10 by ELISA. In
some experiments, recombinant murine IL-12 or anti-rat IL-10 monoclonal
antibody were added together with S2-16 to the cell culture as described
in Materials and Methods. Error bars represent SEMs, and Student’s t-test
was used to determine the significant differences between PBS:CFA-
treated group and S2-16:IFA- or S2-16:CFA-treated group (*P  0.05, **P 
0.005, ***P  0.001).
Figure 3. S2-16 and adjuvant treatment affected cytokine production of DCs.
TNF- production was increased in S2-16:CFA DCs as well as IL-12p40
mRNA, whereas increased IL-10 production was observed for S2-16:IFA DCs.
Lewis rats were injected with S2-16:IFA or S2-16:CFA as a control, or left
untreated. Fourteen days later, DCs were isolated from spleens by positive
selection using OX62 monoclonal antibody and were stimulated by LPS or
CpG-containing oligonucleotide with anti-rat CD40 antibody. TNF- and
IL-10 production from DCs in culture supernatants were measured by ELISA.
IL-12p40 mRNA expression in rat DCs were measured by quantitative real-
time PCR. Rat G3PDH was used as an endogenous control to allow for
relative mRNA quantification. Cytokine mRNA levels are presented as fold
increase in gene expression observed in triplicate wells of LPS and anti-CD40
antibody-treated DCs relative to untreated DCs. Error bars represent SEMs,
and Student’s t-test was used to determine the significant differences between
DCs from untreated rats and DCs from S2-16:IFA- or S2-16:CFA-treated rats
(*P  0.05, **P  0.005).
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cytokines TNF- and IL-12 but a higher amount of regu-
latory cytokine IL-10 than S2-16:CFA-induced DCs after
activation.
Polarized CD4 T-Cell Responses after Culture
with DCs
We then wanted to determine whether DCs derived from
S2-16:IFA and S2-16:CFA-treated rats differed in stimu-
lating T-cell reactivity to S2-16. To address this question,
we co-cultured purified DCs from S2-16:IFA- or S2-16:
CFA-treated and naı¨ve rats at various concentrations with
purified CD4 T cells from these groups of rats, together
with S2-16 peptide. After 96 hours, supernatants and
cells were collected to measure the cytokine production
and cell proliferation. As shown in Figure 4A, S2-16:CFA
CD4 T cells proliferated at comparable levels when
cultured with S2-16:CFA DCs and S2-16:IFA DCs. How-
ever, S2-16:CFA CD4 T cells were promoted by S2-16:
IFA DCs to produce more IL-10 than when they were
cultured with S2-16:CFA DCs (Figure 4A). In contrast,
they produced the highest level of IFN- when cultured
with S2-16:CFA DCs (Figure 4A). On the other hand,
S2-16:IFA CD4 T cells were found to be promoted by
S2-16:CFA DCs to proliferate at a higher level and pro-
duce more IFN-; and in addition their IL-10 production
was high when stimulated with either IFA DCs or CFA
DCs (Figure 4B). Naı¨ve CD4 T cells showed minimal
difference at proliferative responses and IFN- produc-
tion after stimulation with either S2-16:CFA DCs or S2-16:
IFA DCs, where their proliferation and IFN- production
levels were higher than stimulation with naı¨ve rat DCs
(Figure 4C). This indicated that differentiated cytokine
production and proliferation observed in Figure 4, A and
B, did not result from DC proliferation, although both
S2-16:CFA and S2-16:IFA DCs were activated and had
T-cell-stimulating effects.
We also performed intracellular IL-10 staining of DCs
and CD4 T cells in co-culture to more accurately exam-
ine the IL-10 production from T cells. Figure 4D showed
that most of the IL-10 was produced by CD4 T cells in
the co-culture. In addition, S2-16:IFA DCs but not S2-16:
CFA DCs, when co-cultured with CD4 T cells from S2-
16:CFA and S2-16:IFA-treated rats, promoted CD4 T
cells from both groups to produce more IL-10 (Figure
4D). Taken together, these results suggested that the
intrinsic altered immune stimulatory capacity of DCs was
responsible for functional polarization of S2-16-reactive T
cells after S2-16:IFA administration.
Adoptive Transfer of IL-10-Producing DCs
Prevented EAM Induction
To directly demonstrate that DCs contribute to the regu-
lation of myocarditis, we performed a DC adoptive trans-
fer. DCs were purified from S2-16:IFA-treated, control
S2-1:IFA-treated, PBS:IFA-treated, S2-16:CFA-treated, or
naive rats and stimulated in vitro with LPS and anti-CD40
together with S2-16 peptide for 12 hours before transfer.
As shown in Table 3, transfer of DCs from S2-16:IFA-
primed rats to recipient rats before S2-16:CFA challenge
prevented myocarditis. Transfer of DCs from S2-1:IFA-
primed or PBS:IFA-primed rats also resulted in protection
against myocarditis, which suggested that the protection
provided by DC transfer was not antigen-specific. In
contrast, S2-16:CFA-induced DCs and naı¨ve DCs did not
have a protective effect. In addition, blocking of IL-10
Figure 4. Polarized CD4 T-cell response after culture with DCs of S2-16 and
adjuvant-treated rats: S2-16:IFA DCs promoted CD4 T cells to produce more
IL-10, whereas S2-16:CFA DCs promoted IFN- production from CD4 T
cells. Lewis rats were treated with S2-16:IFA or S2-16:CFA. Fourteen days
later, CD4 T cells and DCs were isolated from spleens of treated rats or
untreated naı¨ve rats, and co-cultured together with S2-16 peptide. Prolifera-
tion of cells was measured by 3H-thymidine incorporation after 96 hours.
Cytokine production in cell culture supernatants was measured by ELISA. A:
Proliferative response, IL-10, and IFN- production by CD4 T cells from
S2-16:CFA-treated rats after co-culture (5  105 CD4 T cells) with DCs from
three groups of rats at various concentrations. B: Proliferative response and
IL-10 and IFN- production of CD4 T cells from S2-16:IFA-treated rats after
co-culture (5  105 CD4 T cells) with DCs at various concentrations. C:
Proliferative response and IFN- production of CD4 T cells from naive rats
after co-culture (5  105 CD4 T cells) with DCs at various concentrations.
Error bars represent SEMs. Mann-Whitney test was used to determine the
difference between S2-16:IFA DC or S2-16:CFA DC versus naı¨ve DC groups
(proliferation and IFN-), and S2-16:IFA DC versus S2-16:CFA DC groups
(IL-10). *P  0.05, **P  0.005. D: Intracellular staining suggested that
S2-16:IFA DCs induced higher level IL-10 production from CD4 T cells than
S2-16:CFA DCs. DCs were purified from spleens of S2-16:CFA- or S2-16:IFA-
treated rats, and cultured with purified CD4 T cells from these groups of
rats, together with S2-16 peptide. Cells were removed from co-culture on day
4 and stained for CD4 cells and intracellular IL-10-positive cells. Numbers
denote percentage of cells in each quadrant. The data are representative of
two to three independent experiments with similar results.
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production from S2-16:IFA DCs by anti-rat IL-10 antibody
treatment in vitro inhibited their protective effects, as
shown when recipients of these DCs developed myocar-
ditis after challenge (Table 3). Therefore, the adoptive
transfer directly demonstrated that DCs from S2-16:IFA-
treated rats have a regulatory effect, and antibody
against IL-10 reversed the effects of S2-16:IFA DCs on
protection of EAM.
Discussion
Our present study examined cellular mechanisms and
the role of DCs in regulation of S2-16:IFA-induced pro-
tection to EAM. Cardiac myosin-derived cryptic patho-
genic peptide S2-16:CFA-induced EAM was prevented in
the Lewis rat by pretreatment with the same peptide in
IFA. Adoptive transfer of S2-16:IFA-primed splenocytes
suppressed the induction of myocarditis, however, those
splenocytes could be rendered pathogenic after stimu-
lation with IL-12. S2-16:IFA treatment induced altered
cytokine secretion by autoreactive T cells and DCs. DCs
were found to up-regulate their own production of IL-10
after S2-16:IFA treatment and to promote S2-16-specific
T cells to produce higher levels of IL-10 and reduced
IFN-. Adoptive transfer of anti-IL-10-treated S2-16:IFA
splenocytes failed to protect recipients from myocarditis.
Finally, S2-16:IFA-induced IL-10-producing DCs trans-
ferred tolerance, which directly demonstrated that DCs
contributed to S2-16:IFA-induced protection.
In our Lewis rat EAM model, protection against myo-
carditis induced by S2-16:IFA treatment did not abrogate
the activation of autoreactive T cells. The recall prolifer-
ation of S2-16:IFA-induced splenocytes was similar to
that of S2-16:CFA-induced splenocytes. In addition,
IgG1, IgG2a, and IgG2b antibodies against peptide
S2-16 were detected in S2-16:IFA-treated rats and were
comparable to those in CFA-primed rats (unpublished
data). Therefore, both antibody production and T-cell
proliferation responses were very similar in protected and
diseased rats. Despite the strength of S2-16-reactive lym-
phocyte proliferation, no cellular infiltration was detect-
able in protected rat hearts, which was accompanied by
a high level of regulatory cytokine IL-10 production by
S2-16-specific T cells in those rats. These results do not
support clonal deletion or anergy of autoreactive immune
cells, although such possible mechanisms were indi-
cated by some previous reports that studied antigen and
IFA-induced immunity.54,55,57,61,62 The different results
may be explained by administration of different antigen
doses and routes that induce different levels of tolerance.
Active regulation is an important mechanism of immune
tolerance. Such tolerance does not necessarily mean the
lack of immune responses, and can be associated with
an activation of immune cells that have regulatory ef-
fects.63–65 We showed that peptide S2-16:IFA adminis-
tration induced regulatory cells (T cells and DCs) that
have protective effects. First, S2-16-reactive lymphocytes
from protected rats produced a higher amount of IL-10.
IL-10 has been implicated to be a suppressive cytokine
that is produced by DCs and regulatory T cells and
mediates the down-regulation of immune responses.66
Second, cells from S2-16:IFA-treated rats actively sup-
pressed myocarditis induction on adoptive transfer into
syngeneic rats. Third, IL-10 blockade of S2-16-reactive
splenocytes by antibody treatment abrogated immune
tolerance generation, which indicated the important role
of IL-10 and regulatory cells in S2-16:IFA-induced pro-
tection. Although we only used in vitro anti-IL-10 antibody
treatment in this study, we would think IL-10 blockade of
S2-16-specific T cells in this way was effective enough to
inhibit the protective nature of those T cells. A control
nonmyocarditic peptide S2-1:IFA treatment did not have
protective effects. As we expected, S2-16:IFA pretreat-
ment or primed splenocytes also did not prevent cardiac
myosin-induced myocarditis (data not shown), which in-
dicated that S2-16 may not be the only myocarditic
epitope in cardiac myosin. These results suggested that
the protection was antigen-specific and required regula-
tory cytokine production by antigen-specific T cells. Fur-
ther studies shall be done to determine whether IL-10-
producing regulatory cells exert their effects by direct
contact or indirect mechanisms.
On the other hand, T cells of S2-16:IFA-treated rats
have myocarditic potential as well. Although splenocytes
induced by S2-16:IFA produced lower amounts of Th1
cytokines IFN- and IL-2, these cytokines were primarily
up-regulated when S2-16:IFA cells were stimulated with
IL-12 or encountered DCs from S2-16:CFA-immunized
rats. S2-16:IFA-induced cells regained their pathogenic-
ity and transferred myocarditis into recipient rats after
stimulation in vitro with IL-12. These results were consis-
tent with previous studies that suggested that T cells
induced by antigen:IFA may be in a transitional state and
retain the ability to differentiate into pathogenic effectors
under Th1-polarizing conditions.56,67,68 Our data also
suggested that antigen:IFA-induced tolerance to myocar-
ditis is a dynamic process and can be broken by strong
inflammatory stimuli produced by APCs.68–70 After expo-
Table 3. DCs from Tolerized Rats Transferred Tolerance to
Naı¨ve Rats
Donor of DCs
Recipient with EAM
after challenge
Mean score
(0–4)  SD
S2-16:IFA 1/8 0  0.3*
S2-16:IFA
( anti-IL-10)
4/6 1.9  1.8
S2-1:IFA 0/3 0†
PBS:IFA 0/3 0†
S2-16:CFA 6/8 1.6  1.1
Naive 4/5 1.7  1.1
Lewis rats were treated with S2-16:IFA. Control rats were treated
with S2-16:CFA, S2-1:IFA, PBS:IFA, or left untreated. Splenic DCs were
obtained from each group of animals 2 weeks after treatment, and were
cultured in vitro with peptide S2-16, together with LPS plus anti-rat
CD40 antibody for 12 hours. One group of S2-16:IFA-treated rats were
incubated with antibody against rat IL-10 in addition. DC aliquot (106)
was injected into each naı¨ve Lewis rat intravenously. The recipients
were concomitantly challenged by active immunization with S2-16:CFA
after transfer, and sacrificed 3 weeks after challenge. Myocarditis was
identified in the fixed heart sections by histopathological examination.
*P  0.01 for groups: S2-16:IFA versus naı¨ve, S2-16:IFA versus
S2-16:IFA ( anti-IL-10), and S2-16:IFA versus S2-16:CFA.
†P  0.05 for groups: S2-1:IFA versus naı¨ve, and PBS:IFA versus
naive.
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sure to high doses of exogenous IL-12, S2-16:IFA-in-
duced cells produced increased IFN- but not IL-10 in
response to S2-16. The reversal of protection by IL-12
exposure, therefore, might be mediated by enhanced
Th1 effector function that could overcome the protective
effects of IL-10-producing regulatory cells. Although dis-
ease induction required Th1 effectors, the protection in-
duced by S2-16:IFA was not simply a Th2 cytokine effect
because it was antigen-specific and transferable. Be-
cause we did not investigate functional perspective of
T-cell clones, we do not know if a single cell or clonal
population can polarize under pressure from DCs, but
our data strongly suggest that S2-16-reactive T cells can
be controlled by DCs. S2-16 and IFA administration in our
model may induce mixed T-cell populations that contain
partially polarized T-helper cells and activated regulatory
cells recognizing S2-16, and the result of immune re-
sponses depends on the balance of these cell functions.
A mixed T-cell population may also be induced by S2-
16:CFA treatment, in which activated Th1 effectors gen-
erally are more dominant than regulatory cells and may
explain why S2-16:CFA pretreatment also induced some
protection against myocarditis as shown in Table 1.
APCs play a key role in deciding the fate of a T-cell
population.71,72 DCs are professional APCs specialized
for the initiation of not only effector T cells but also regu-
latory T-cell immunity.51,73 The tolerogenic DCs have
been implicated in some tolerance studies.45,74–76 For
example, pulmonary DCs producing IL-10 have been
shown to mediate tolerance induced by intranasal admin-
istration of antigen.74 DCs generated in the presence of
agents that inhibit their maturation-induced T-cell unre-
sponsiveness in vitro and in vivo.75,76 The role of DCs and
their cytokines in antigen:IFA-induced protection have
not been previously characterized. In our study, we
showed that the altered function of S2-16-reactive T cells
resulted from the effects of DCs. Activated DCs isolated
from S2-16:IFA or CFA-primed rats secreted different
cytokines, and also polarized S2-16-reactive CD4 T
cells to have differentiated function. A marked difference
in IL-10 production of S2-16:IFA T cells after co-culturing
with CFA DCs or IFA DCs was detected by flow cytometry
analysis (Figure 4D) but not cytokine ELISA (Figure 4B).
The difference might result from the sensitivity of different
experimental techniques. Alternatively, the data may sug-
gest that terminally differentiated IFA CD4 T cells are
more dominant than DCs and their IL-10 production is not
easily changed by DCs. Despite the fact that S2-16:IFA
CD4 T cells produced high levels of IL-10, the T cells
were still able to make IFN- under S2-16:CFA DC stim-
ulation, which may suggest that different populations of T
cells secrete different cytokines in response to the DCs.
In our experiments, naı¨ve T cells and activated CFA or
IFA T cells gave similar proliferation profiles when cul-
tured with DCs (Figure 4; A to C). The peak of proliferation
of activated T cells may be earlier than for naı¨ve T cells,
and we therefore may not have observed it under our
experimental conditions. In addition to our in vitro studies,
we also showed that IL-12 and IL-10, key DC cytokines,
were critical to control the fate of S2-16:IFA-induced S2-
16-specific lymphocytes in vivo. Furthermore, S2-16:IFA-
induced IL-10-producing DCs transferred tolerance or
protection against myocarditis. Therefore, our results di-
rectly demonstrated that antigen-specific immunity or tol-
erance induced by S2-16:IFA was regulated by DCs
secreting different cytokines.
It remains controversial how DCs are involved in the
maintenance of tolerance to self-antigen especially at the
periphery. It has been proposed that specialized regula-
tory DCs are involved in tolerance,77–80 however, the
evidence for this is still fragmentary. Another more ac-
cepted concept is that the state of development or acti-
vation of DCs decides if those particular DCs will act as
an immunogenic or tolerogenic mediator.50,81 The clas-
sical two-signal model proposes that immature DCs that
deliver signal 1 in the absence of signal 2 induce the
anergic or tolerance state in T cells.25 New evidence
shows that DC maturation may be a process including
several stages that could be distinguished not only by
their activation marker expression but also by their cyto-
kine production and migration capacity.73,82 Our study
showed that DCs from S2-16:IFA- or CFA-treated rats had
different cytokine production as well as different T-cell-
polarizing function. Similar results have been shown in
other models of immune tolerance.74,83 We were not able
to observe a difference in their maturation state at the
time point when we harvested cells, and DCs from both
groups had mature DC features (data not shown). Other
molecules on DCs that deliver signals, such as CD40,
may also play an important role in determining cytokine
production from T cells.67,83 DCs induced by S2-16:IFA
immunization may exert their protective effect by promot-
ing S2-16-specific T cells to reduce their Th1 polarization
and increase IL-10 production. The regulation of T cells
by DCs may not be antigen-specific, because DCs from
PBS:IFA- and S2-1:IFA-treated rats also prevented myo-
carditis induction. Although DCs produced regulatory
cytokines that influenced the T cells, it is the antigen-
specific T cells that finally deliver protection against myo-
carditis. Therefore, the data clearly link protection to both
innate and adaptive antigen-specific immune function.
Because development of myocarditis may involve multi-
ple myocarditic epitopes of cardiac myosin, such a DC-
induced, antigen-specific T-cell-mediated protection
may have potential application in the development of
therapies for myocarditis. Defined mechanisms of how
regulatory DCs control T-cell function in this model sys-
tem is still under study. The ratio of IFN--producing
effector T cells and IL-10-producing regulatory T cells
may be a dynamic process controlled by DCs and the
cytokine environment that directs the outcome of S2-16-
specific immune responses in our model system.
In summary, we demonstrated that antigen-specific
protection induced by cardiac myosin peptide and IFA
treatment in Lewis rat EAM was closely associated with
antigen-specific T-cell function controlled by DCs and
their secreted cytokines. In humans with myocarditis, it is
likely that alteration in DC function and cytokine produc-
tion may be important in development of disease. Mod-
ulation of cardiac-specific immune responses provides a
powerful tool to investigate the pathogenic mechanisms
involved in autoimmune myocarditis. Our study may also
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shed light on potential development of antigen-specific
immune therapy to control chronic myocarditis.
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